Immuron Limited (IMRN)
| Market Cap | 20.90M |
| Revenue (ttm) | 1.74M |
| Net Income (ttm) | -2.02M |
| Shares Out | 5.68M |
| EPS (ttm) | -1.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,123 |
| Open | 3.65 |
| Previous Close | 3.60 |
| Day's Range | 3.60 - 3.73 |
| 52-Week Range | 3.40 - 9.48 |
| Beta | 1.85 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About IMRN
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive func...
Financial Performance
In 2020, Immuron's revenue was 2.52 million, an increase of 5.49% compared to the previous year's 2.39 million. Losses were -2.93 million, -37.14% less than in 2019.
Financial numbers in millions AUDFinancial StatementsNews
Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies were conducted independently by the Hadassah Medical ...
Immuron Director resignation
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeuti...
Immuron planned Acquisition of R&D Vaccine Company
MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeuti...
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
Key Points
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutic...
Immuron Receives AUD $358,280 R&D Tax Concession Refund
MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics...
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine
Key Points
Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing ora...
Why Nanocap Biotech Immuron's Stock Is On A 2-Day Run
Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) were rallying for the second day in a row Tuesday following an announcement concerning a potential COVID-19 treatment option.
Immuron's stock pulls back but still nearly doubles after stock offering
Shares of Immuron Ltd. IMRN, +56.58% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered d...
Why Immuron’s New COVID-19 Study Is a Game Changer
Immuron Ltd. (NASDAQ: IMRN) continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome cor...
Immuron Announces $20.0 Million Registered Direct Offering
MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeut...
Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points
MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeut...
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
Key Points
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
Key Points
Can the 800% Gain in Immuron Be Rationalized Very Easily?
The day traders are back at it, chasing stocks on news with very few thoughts about what the fundamentals may be if the good news pans out.
Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA
The U.S.-listed shares of of Immuron Ltd. IMRN, 1,152.32% skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday
Immuron's Stock Surges 300% On US Navy Contract
Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) are on a roll Tuesday on the back of financing deal for one of its pipeline assets.
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute In...
Key Points
Immuron Board Relinquish Cash Payment of Fees
MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeu...
Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%
Key Highlights:
Resignation of CEO & Director and cost cutting amidst COVID-19
MELBOURNE, Australia, March 25, 2020 (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Comp...